Artificial Intelligence (AI) is transforming the pharmaceutical industry by accelerating drug discovery, improving target identification, and enabling precision medicine through advanced data analytics and computational capabilities. As AI becomes increasingly embedded across the drug development lifecycle, governments are playing a pivotal role in fostering innovation through strategic investments, robust digital infrastructure, genomic data initiatives, adaptive regulatory frameworks, and cross-sector collaborations. Globally, leading economies such as the United States, European Union, and India are building collaborative innovation ecosystems that integrate government agencies, academia, healthcare providers, technology companies, startups, and the pharmaceutical industry to enable faster, safer, and more responsible AI-driven drug discovery. This whitepaper explores global government-led initiatives, benchmarks leading AI drug discovery ecosystems, highlights India's strategic opportunity, and examines the policy, infrastructure, and research partnerships required to position the country as a global leader in AI-enabled pharmaceutical innovation.
Key Statistical Highlights
- The U.S. National Institutes of Health (NIH) invests over USD 47 billion annually in biomedical research, while the European Union has committed €93.5 billion under Horizon Europe (2021–2027) to strengthen collaborative research and AI-driven healthcare innovation.
- India's IndiaAI Compute Platform has onboarded more than 38,000 GPUs, supported by the ?10,371.92 crore IndiaAI Mission, providing researchers, startups, and academic institutions with large-scale AI computing capabilities for genomics and drug discovery.
- The Genome India Project has sequenced 10,000 whole genomes representing 85 genetically diverse population groups and identified nearly 180 million genetic variants, establishing a strategic genomic foundation for AI-driven precision medicine and pharmaceutical research.
- Since 2016, the U.S. FDA has received more than 500 AI-enabled drug submissions, reflecting the rapid integration of artificial intelligence into pharmaceutical development and regulatory decision-making.
About The Author
Sonika Bhardwaj
Sonika is a Business Research Analyst with over two years of hands-on experience in business and market research, supporting clients across different geographies and diverse industries. She brings expertise in both primary and secondary research, including conducting in-depth interviews, performing competitive benchmarking, and developing high-quality syndicated reports. She excels at translating complex information into clear, actionable insights through well-structured reports and visually compelling dashboards. Her analytical strengths are supported by advanced proficiency in Excel, Power BI, and data visualization techniques. Recognized for her organized approach, thorough work style, and ability to deliver polished, client-ready outputs, Sonika consistently contributes to strategic decision-making and business growth initiatives.
Know More